Tumor cells can evade immune surveillance by altering the glucose and glutamine metabolic pathways, thereby affecting the expression of PD-L1, which in turn affects the efficacy of PD-1/PD-L1 inhibitors (27). Here, CD274 is linked to neoplasm.